+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Idarubicin"

Anthracycline Market Report 2025 - Product Thumbnail Image

Anthracycline Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Acute Myeloid Leukemia Market Report 2025 - Product Thumbnail Image

Acute Myeloid Leukemia Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Idarubicin is an oncology drug used to treat acute myeloid leukemia (AML). It is a type of anthracycline antibiotic, which works by inhibiting the growth of cancer cells. Idarubicin is administered intravenously and is usually given in combination with other chemotherapy drugs. It is also used to treat other types of cancer, such as lymphoma and multiple myeloma. Idarubicin is generally well tolerated, but can cause side effects such as nausea, vomiting, hair loss, and anemia. Idarubicin is available in both generic and branded forms. It is marketed by several pharmaceutical companies, including Pfizer, Bristol-Myers Squibb, and Teva Pharmaceuticals. It is also available in combination with other drugs, such as cytarabine and daunorubicin. The Idarubicin market is highly competitive, with many companies offering similar products. Companies in the market include Pfizer, Bristol-Myers Squibb, Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. Show Less Read more